ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Clinical Trials Study |
Article Title |
Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Shintaro Tsukinaga, Mikio Kajihara, Kazuki Takakura, Zensho Ito, Tomoya Kanai, Keisuke Saito, Shinichiro Takami, Hiroko Kobayashi, Yoshihiro Matsumoto, Shunichi Odahara, Kan Uchiyama, Hiroshi Arakawa, Masato Okamoto, Haruo Sugiyama, Kazuki Sumiyama, Toshifumi Ohkusa and Shigeo Koido |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Ministry of Education, Culture, Sports, Science and Technology of Japan |
|
|
Corresponding Author |
Shigeo Koido, MD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567,
Japan. shigeo_koido@jikei.ac.jp |
Key Words |
Chemoimmunotherapy; Dendritic cell; Delayed-type hypersensitivity; Interleukin-6; Interleukin-8; Pancreatic cancer; Wilms’ tumor 1 |
Core Tip |
We recently reported a phase 1 clinical study in pancreatic cancer patients using dendritic cells (DCs) pulsed with multiple major histocompatibility complex class?Ⅰ?and Ⅱ-restricted Wilms’ tumor 1 (WT1) epitopes (DC/WT1-Ⅰ/Ⅱ) in combination with chemotherapy. Little is known about the prognostic markers for the clinical outcomes of chemoimmunotherapy. We exa-mined the association of plasma levels of interleukin (IL)-6/-8 with WT1-specific immune responses and clinical outcomes in pancreatic cancer patients treated with chemotherapy combined with DC/WT1-Ⅰ/Ⅱ. The study demonstrates that prolonged low levels of plasma IL-6/-8 in pancreatic ductal adenocarcinoma patients may be a prognostic marker for the clinical outcomes of chemoimmunotherapy. |
Publish Date |
2015-10-19 09:14 |
Citation |
Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sugiyama H, Sumiyama K, Ohkusa T, Koido S. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J Gastroenterol 2015; 21(39): 11168-11178 |
URL |
http://www.wjgnet.com/1007-9327/full/v21/i39/11168.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v21.i39.11168 |